Achieve Life Science Inc. (ACHV)

[Kallie]

I just found this not sure if anyone has seen it or not. They are collaborating with 2 other companies that are much much larger link included look on page 11. I am trying to find out if one of the 3 is the one that is due for approval the first quarter of this year.Might explain the movement something really good might be coming this way. Ash you have done a fantastic job here and I thank you very much. What are your thoughts on this?

Developments in Ionis Pharmaceuticals’ Oncology Segment
By Mike Benson | Apr 14, 2016 2:49 pm EDT
Oncology segment
Ionis Pharmaceuticals (IONS) is developing drugs for the treatment of various types of cancer, including prostate cancer and lung cancer. These drugs are being developed in collaboration with OncoGenex Pharmaceuticals (OGXI) and AstraZeneca (AZN).

Drug in Phase III study
Custirsen is Ionis’s only drug in the oncology segment that’s in a Phase III clinical study. Custirsen was discovered and developed in collaboration with OncoGenex. It’s designed to improve survival in patients with advanced cancer. There are two Phase III studies: AFFINITY and ENSPIRIT. The studies are being conducted by OncoGenex to evaluate custirsen as a second-line treatment of patients with castration-resistant prostate cancer and non-small cell lung cancer. The FDA (U.S. Food and Drug Administration) has granted custirsen a fast-track designation for a combination treatment with docetaxel for the treatment of metastatic prostate cancer.

http://marketrealist.com/2016/04/ioniss-metabolic-segment-phase-phase-ii-studies/